The anti-obesity medicine tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight problems, lowered obesity-associated breast most cancers development in a mouse mannequin, based on a research being offered Saturday at ENDO 2025, the Endocrine Society’s annual assembly in San Francisco, Calif.
“Weight problems is a big threat issue for breast most cancers, and whereas it is extremely preliminary information, our research in mice counsel that these new anti-weight problems medication could also be a method to scale back obesity-associated breast most cancers threat or enhance outcomes,” stated research writer Amanda Kucinskas, B.S., a Ph.D. candidate within the labs of Drs. Erin Giles and Kanakadurga Singer on the College of Michigan in Ann Arbor, Mich.
Present analysis has proven that having weight problems can result in worse breast most cancers outcomes in comparison with those that should not have weight problems, and weight reduction can enhance outcomes. Nonetheless, there are a lot of challenges with conventional weight reduction strategies.
Kucinskas and colleagues leveraged tirzepatide, certainly one of a brand new class of efficient anti-obesity medicines that concentrate on GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. The researchers sought to be taught whether or not or not tirzepatide would scale back obesity-associated breast most cancers development.
This mouse research included 16 mice. The 9-week-old C57BL/6 mice have been fed a 40% high-fat food regimen and housed in a heat setting to induce weight problems. At 32 weeks of age, the mice with weight problems have been randomly assigned injections of tirzepatide or a placebo each different day for 16 weeks. Tumor volumes have been measured twice weekly.
The researchers discovered that the anti-obesity drug lowered physique weight and physique fats by roughly 20% in mice, much like the quantity of weight reduction achieved by girls on this drug. They discovered this was primarily attributable to a lack of adipose mass, with a discount in adipose depot weights in comparison with controls.
The anti-obesity drug additionally lowered tumor quantity in comparison with the controls. On the finish of the research, the researchers discovered that tumor quantity was considerably correlated with physique weight, complete adipose mass and the quantity of fats saved within the liver.
“Whereas these are very preliminary outcomes, they counsel that this new anti-obesity drug might also have a helpful impression on breast most cancers outcomes,” Kucinskas stated.
Ongoing research are underway in collaboration with Dr. Steve Hursting’s lab on the College of North Carolina at Chapel Hill to separate the weight reduction from the tumor-specific results of tirzepatide.
Quotation:
Mouse research finds tirzepatide slowed obesity-associated breast most cancers development (2025, July 12)
retrieved 12 July 2025
from https://medicalxpress.com/information/2025-07-mouse-tirzepatide-obesity-breast-cancer.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
